Differences in HbA1c do not explain cardiovascular benefits in the treatment of type 2 diabetes

Treatment that reduce the hyperglycemic burden in patients with tye 2 diabetes reduce the risk of microvascular complications – as retinopathy, nephropathy and neuropathy. But where are the link to the cardiovascular protection we have seen in the treatment of type 2 diabetes with SGLT-2 inhibitor and GLP-1 receptor agonists. In this MEDtalk you will get an answer from Odd Erik Johansen, Bærum Hospital, Oslo University Hospital.